Price Cuts On MS Drugs Lead UK's NICE To Reverse Earlier Rejection
Executive Summary
Avonex, Copaxone, Extavia and Rebif have all been recommended for use on England's National Health Service after their prices were reduced to improve their cost-effectiveness. However, Betaferon remains too expensive to be given a positive recommendation, according to the health technology assessment body, NICE.